The Food and Drug Administration previously issued finalized guidance in July 2026 titled "Psychedelic Drugs: Considerations for Clinical Investigations" to assist sponsors developing psychedelic drugs.

552c7ae14

Psychedelics

Mind-altering substances like psilocybin, LSD, MDMA, and ayahuasca and their therapeutic and cultural use.

83 claims·1 news story

0